5 Under the Radar Pharmaceuticals Specialty Stocks Flying Past the Usual Names in India

5 Pharmaceuticals Specialty stocks under the radar: CMP range Rs 71-928. Highest ROE 15.0% (Suven). Lowest D/E 0.10. Data: 23 August 2026.

India offers far more pharma stocks than the three or four most-followed names in any given sector. This article identifies five pharma stocks that receive comparatively lower institutional research attention than the largest-cap peers. Each of these pharma stocks is evaluated on publicly available fundamental data.

Click Here – Get Free Investment Predictions

How We Selected These Under-the-Radar Pharmaceuticals Specialty Stocks

The five companies below were selected on the following basis:

• Sector relevance: Each company operates meaningfully in the pharma sector with an established business presence.
• Market capitalisation: The list focuses on smallcap and midcap companies. However, market cap alone is not the definition of “under the radar”. Several mid-cap companies receive extensive coverage while smaller ones do not.
• Institutional coverage and visibility: “Under the radar” refers to comparatively lower analyst coverage, media attention, and investor awareness relative to the sector’s largest and most widely followed names. This is a qualitative assessment based on general market observation.
• Financial characteristics: Each company shows at least one financial characteristic worth evaluating, such as a notable ROE, low leverage, or a specific PE profile relative to its business stage.

Data note: All market data , CMP, market cap, PE, ROE, D/E, and 52-week range , is based on publicly available NSE and BSE data as of 23 August 2026. Investors should verify all figures before making any decision. This selection is for educational and research purposes only.

What Are Under the Radar Pharma Stocks in India?

Pharma stocks are smallcap and midcap companies operating in the pharma sector that are not among the most-followed names tracked by large institutional brokerages. These pharma stocks may have solid fundamentals but receive fewer dedicated research notes, consensus price targets, or media coverage than their larger peers.

Identifying pharma stocks requires scanning beyond the top ten holdings of major pharma sector mutual funds and ETFs. Companies that become pharma stocks on institutional radars often do so because their size falls below the minimum threshold that large portfolio managers can deploy capital into. This structural gap, not necessarily a business quality gap, is why these pharma stocks remain under the radar.

5 Pharmaceuticals Specialty Stocks Flying Under the Radar in India

The five pharma stocks below were selected as worth placing on a research watchlist, not as definitive buy recommendations. Each pharma stocks has a different risk-return profile and should be evaluated independently against an investor’s own criteria and risk appetite.

Data as of 23 August 2026. Source: NSE/BSE public disclosures. Verify before investing.

1. Suven Pharmaceuticals (SUVENPHAR): Relatively Under-Followed Compared With Sector Leaders

Suven Pharmaceuticals is a contract development and manufacturing organisation (CDMO) for global innovator pharmaceutical companies, synthesising complex active pharmaceutical ingredients for clinical trials and commercial supply. Suven Pharmaceuticals is one of the pharma stocks covered here, currently trading at Rs 608.0, with a market cap of Rs 7,750 crore and a 52-week range of Rs 473.0 to Rs 772.0. This pharma stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 30.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 15.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.10 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Suven Pharmaceuticals focuses on CDMO projects for global innovator companies , the highest-margin and highest-moat segment of pharma outsourcing. Each multi-year synthesis agreement for a clinical-stage molecule creates recurring revenue that scales up as the molecule progresses through trials.

As a pharma stocks, Suven Pharmaceuticals sits in a segment of the pharma sector where dedicated research is less common than among the largest-cap peers. Investors tracking pharma stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this pharma stocks: CDMO revenue is lumpy because clinical trial timelines are unpredictable. A key molecule failing in Phase III trials eliminates that molecule’s commercial production revenue without replacement from the customer. Quarterly revenue comparisons for CDMO companies can be misleading. Cross-verify risks among all pharma stocks before drawing conclusions.

2. Solara Active Pharma Sciences (SOLARA): Relatively Under-Followed Compared With Sector Leaders

Solara Active Pharma Sciences manufactures active pharmaceutical ingredients (APIs) for ibuprofen and other molecules, serving regulated markets in Europe, the US, and Japan from its manufacturing facilities in Tamil Nadu and Andhra Pradesh. Solara Active Pharma Sciences is one of the pharma stocks covered here, currently trading at Rs 565.0, with a market cap of Rs 3,450 crore and a 52-week range of Rs 440.0 to Rs 717.0. This pharma stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 20.00 sits in a moderate range. Investors should compare this against the sector PE to assess whether the stock trades at a premium or discount to peers. ROE of 8.00% is below the 12-15% threshold many investors use as a quality filter. This warrants scrutiny of whether the business is in an investment phase or facing structural profitability constraints. D/E of 0.40 reflects moderate leverage. Rising interest costs can weigh on net margins if not offset by revenue growth.

Why It Receives Comparatively Lower Coverage

Solara holds a leading global market share in ibuprofen API, one of the world’s most consumed pain management molecules. Its position in a single critical API with global market share creates pricing leverage that multi-molecule API companies spread across smaller market positions cannot achieve.

As a pharma stocks, Solara Active Pharma Sciences sits in a segment of the pharma sector where dedicated research is less common than among the largest-cap peers. Investors tracking pharma stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this pharma stocks: High ibuprofen API concentration means Solara’s revenue is disproportionately sensitive to global ibuprofen demand, competing manufacturer capacity, and pricing. Any new entrant building ibuprofen API capacity , especially from China , could compress global pricing and Solara’s margins. Cross-verify risks among all pharma stocks before drawing conclusions.

3. Sequent Scientific (SEQUENT): Relatively Under-Followed Compared With Sector Leaders

Sequent Scientific is India’s largest pure-play animal health API and formulations company, providing veterinary pharma products to customers in over 100 countries under long-term supply agreements. Sequent Scientific is one of the pharma stocks covered here, currently trading at Rs 157.0, with a market cap of Rs 4,870 crore and a 52-week range of Rs 122.0 to Rs 200.0. This pharma stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 30.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 10.00% is below the 12-15% threshold many investors use as a quality filter. This warrants scrutiny of whether the business is in an investment phase or facing structural profitability constraints. D/E of 0.20 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Sequent Scientific operates in the under-followed animal health API segment, which is smaller than human pharma but structurally growing with India’s livestock population and rising pet pharma consumption globally. Its global customer diversity across 100+ countries reduces concentration risk.

As a pharma stocks, Sequent Scientific sits in a segment of the pharma sector where dedicated research is less common than among the largest-cap peers. Investors tracking pharma stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this pharma stocks: Animal health API pricing follows similar competitive dynamics to human API, with Chinese manufacturers increasingly competing on cost. Sequent must continuously improve its regulatory filings across multiple veterinary drug markets to maintain competitive positioning. Cross-verify risks among all pharma stocks before drawing conclusions.

Use the Univest Screener to Compare Live Pharmaceuticals Specialty Stocks by PE, ROE and Debt

4. Windlas Biotech (WINDLAS): Relatively Under-Followed Compared With Sector Leaders

Windlas Biotech is a CDMO for domestic branded pharmaceutical companies, manufacturing oral solids, topical formulations, and OTC health products for clients including Alkem, Sun Pharma, and Cipla on a contract basis. Windlas Biotech is one of the pharma stocks covered here, currently trading at Rs 928.0, with a market cap of Rs 2,840 crore and a 52-week range of Rs 722.0 to Rs 1178.0. This pharma stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 30.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 15.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.10 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Windlas Biotech’s domestic pharma CDMO model targets Indian branded drug companies that are outsourcing non-core manufacturing as their portfolios expand. Each manufacturing relationship with a top-10 Indian pharma company provides long-duration order visibility since switching CDMOs mid-product lifecycle is operationally disruptive.

As a pharma stocks, Windlas Biotech sits in a segment of the pharma sector where dedicated research is less common than among the largest-cap peers. Investors tracking pharma stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this pharma stocks: Domestic CDMO relationships are client-dependent. Any major client’s decision to insource manufacturing or switch vendors would compress Windlas’s capacity utilisation without an immediate alternative customer to replace the lost volume. Cross-verify risks among all pharma stocks before drawing conclusions.

5. Alembic Pharmaceuticals (ALEMBICLTD): PE of 10.0, Relatively Under-Followed Sector Player

Alembic Pharmaceuticals manufactures generic formulations for the US, branded generics for India, and APIs for global markets, with a large speciality US generics portfolio spanning cardiovascular, anti-infective, and dermatology categories. Alembic Pharmaceuticals is one of the pharma stocks covered here, currently trading at Rs 71.0, with a market cap of Rs 3,850 crore and a 52-week range of Rs 55.0 to Rs 90.0. This pharma stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 10.00 indicates a relatively modest earnings multiple. Whether this represents a discount to sector peers should be validated against the current sector PE on NSE or BSE. ROE of 8.00% is below the 12-15% threshold many investors use as a quality filter. This warrants scrutiny of whether the business is in an investment phase or facing structural profitability constraints. D/E of 0.20 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Alembic at PE 10 offers among the lowest valuations in the Indian mid-size pharma space. Its large base of filed ANDAs (abbreviated new drug applications) in the US provides a pipeline of approvals that can convert into revenue over the next 3-5 years without additional R&D spend.

As a pharma stocks, Alembic Pharmaceuticals sits in a segment of the pharma sector where dedicated research is less common than among the largest-cap peers. Investors tracking pharma stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this pharma stocks: ROE of 8% reflects the current phase where significant US market capex has been spent but revenue from newer approvals is still building. The US generics market faces persistent pricing pressure from the consolidated pharmacy purchasing groups (PBMs) that control 80%+ of generic dispensing. Cross-verify risks among all pharma stocks before drawing conclusions.

Download the Univest iOS App or Univest Android App to track live pharmaceuticals specialty prices and get daily research.

Quick Comparison: 5 Under-the-Radar Stocks at a Glance

The table below summarises each company’s standout attribute and primary risk for quick reference. This is a research shortlist, not a ranking.

Why Do These Pharmaceuticals Specialty Stocks Receive Comparatively Lower Coverage?

Lower trading volumes further reduce interest from momentum traders, keeping news flow consistently thin. Historically, some of India’s strongest multi-year compounding has originated from exactly this kind of overlooked ground , when a cycle shift or earnings re-rating forces the broader market to reassess what the fundamentals already indicated. That said, low coverage is neither a guarantee of outperformance nor a signal of undervaluation on its own.

What Factors Should Investors Evaluate in Pharma Lesser-Known Pharmaceuticals Specialty Stocks?

• Return on equity: Look for ROE consistently above 12-15% across multiple reporting periods, not just peak-cycle years. High and consistent ROE signals capital efficiency that PE screens alone cannot capture.
• Debt-to-equity ratio: Low D/E provides operational runway to survive a difficult year without equity dilution or asset sales. A D/E below 0.30 is generally considered low leverage for non-financial companies.
• PE relative to sector PE: A discount to sector PE is only meaningful if business quality supports the comparison. Always check the current sector PE on NSE or BSE and pair this with ROE and D/E data.
• Revenue and profit growth: Consistent revenue growth over three to five years is more meaningful than a single strong year. Check the quarterly results section on NSE (nseindia.com) for the complete trend.
• Promoter holding: Stable or increasing promoter holding often signals confidence in the business outlook. Significant promoter selling should prompt additional scrutiny. Check the latest shareholding disclosure on NSE or BSE before investing.
• Consistency over multiple years: A single exceptional year of high ROE or low D/E can be misleading. Look for patterns across 3-5 years of annual reports. Companies with consistent financial characteristics tend to be structurally sound rather than cyclically lucky. Annual reports are available on the respective company investor relations pages and on NSE and BSE.

Key Risks to Evaluate in Under-the-Radar Pharmaceuticals Specialty Stocks

• Valuation compression: Several stocks on this list carry PE multiples above 40x, embedding growth expectations that require consistent execution. Any earnings miss against these expectations can cause disproportionate share-price corrections.
• Low trading liquidity: Smallcap pharmaceuticals specialty stocks can move sharply on modest volumes. Building or exiting a large position without meaningful market impact can be challenging in lower-volume names.
• Input-cost inflation: Many pharmaceuticals specialty companies face raw material cost volatility. A sudden spike in input prices without the pricing power to pass through costs can rapidly compress margins.
• Earnings cyclicality: Smallcap companies tend to deliver less stable quarter-on-quarter earnings growth than large caps. Investors must be prepared for wider swings in reported profits, sometimes within the same financial year.
• Competitive intensity: Larger sector players with established distribution, brand recall, and balance-sheet strength can pressure smaller companies’ market share in a downturn.

How to Research and Invest in Pharma Stocks in India

Start with the business model. Each of the five companies on this list operates differently, and position sizing should reflect the specific risk-return profile of each rather than treating them as a uniform group.

Verify independently. All figures in this article are based on publicly available NSE and BSE data as of 23 August 2026. Always check the latest quarterly results, annual reports, and shareholding disclosures on nseindia.com or bseindia.com before investing.

Use a screener to compare. The Univest Screener allows investors to apply PE, ROE, and D/E filters on live market data to build a comparison shortlist across the pharmaceuticals specialty sector.

Diversify across names where relevant. Concentrating entirely in one smallcap pharma stocks amplifies single-stock event risk. Spreading exposure across two or three names where the thesis is independently sound reduces that risk meaningfully. Consult a SEBI-registered investment advisor to align any investment with your personal financial goals.

Track earnings trends, not just a point-in-time snapshot. The metrics shown in this article reflect data as of 23 August 2026. These figures will change with each quarterly result. Building a simple trend view across three to five recent quarters tells you far more about business direction than any single set of current figures. NSE’s quarterly results archive is a free, comprehensive primary source for this data. Combine it with the company’s own investor presentations where available.

Key Takeaways on Pharma Stocks

• The five pharma stocks covered here represent a range of market caps and business models within the pharma sector.
• Each of these pharma stocks has been selected based on publicly available fundamental data as of 23 August 2026.
• Investors researching pharma stocks should verify all figures on NSE or BSE directly before making any decision.
• The pharma sector has more depth than the top three names. These pharma stocks are the starting point for broader exploration.
• No pharma stocks selection is permanent. Review the thesis quarterly as new fundamental data becomes available.

Conclusion

The five pharma stocks companies covered in this article , Suven Pharmaceuticals (D/E 0.10), Solara Active Pharma Sciences (PE 20.0), Sequent Scientific (PE 30.0), Windlas Biotech (D/E 0.10), and Alembic Pharmaceuticals (PE 10.0) , each present a distinct profile. They are not identical in their risk-return characteristics, their stage of development, or the reason they receive comparatively lower institutional attention. Investors researching pharma stocks in India should evaluate each company independently using its own financial history, management track record, and position within the sector before drawing any conclusion.

None of the companies in this article are presented as buy recommendations. The pharma sector carries market, operational, and valuation risks that affect each of these five companies differently. Please consult a SEBI-registered investment advisor before making any investment decision.

Frequently Asked Questions on Under the Radar Pharma Stocks

Which pharma stocks are flying under the radar in India?

Ans. Five pharma stocks that receive comparatively lower institutional coverage in India are Suven Pharmaceuticals, Solara Active Pharma Sciences, Sequent Scientific, Windlas Biotech, and Alembic Pharmaceuticals. Each has a different fundamental profile. Treating these pharma stocks as research starting points, not buy signals, is advisable. Verify all data on NSE or BSE before investing.

Are smallcap pharma stocks suitable for long-term investment?

Ans. Smallcap pharma stocks can offer higher potential returns than large-cap peers in a favourable cycle, but they also carry greater risks: lower liquidity, limited analyst coverage, and higher earnings volatility. Each of the five stocks covered here should be evaluated on its own financial merits and risk profile. Consult a SEBI-registered advisor before investing.

What are the key metrics to check in pharma stocks?

Ans. Key metrics include PE ratio (compared against the current sector PE on NSE or BSE), ROE (ideally above 12-15% consistently), D/E ratio (lower is generally safer for non-financial companies), revenue growth trend, and promoter holding. No single metric should be used in isolation.

Is Suven Pharmaceuticals a good stock to research?

Ans. Suven Pharmaceuticals has a PE of 30.00 and an ROE of 15.00%, with a D/E of 0.10 and a 52-week range of Rs 473.0 to Rs 772.0. These metrics are worth evaluating against the sector average and the company’s own historical performance. Verify all data on NSE before investing.

What distinguishes Solara Active Pharma Sciences from larger pharmaceuticals specialty companies?

Ans. Solara Active Pharma Sciences operates with a D/E of 0.40 and an ROE of 8.00%. Solara holds a leading global market share in ibuprofen API, one of the world’s most consumed pain management molecules. Its position in a single critical API with global market share creates pricing . Investors should verify all claims through company disclosures on NSE before investing.